Pharmaceutical companies whose net profit from January to September fell by 300% year-on-year, executives resigned!

At the end of the year, the change of senior management of pharmaceutical companies continued
.
News on December 16, Henan Tailong Pharmaceutical Co.
, Ltd.
(hereinafter referred to as Tailong Pharmaceutical) issued an announcement, announcing that it recently received a written resignation report
from Mr.
Li Hui, vice chairman and director of the company.
Due to his health, Mr.
Li Hui applied to resign as the vice chairman, director and member of the strategic decision-making committee of the ninth board of directors of the company, and at the same time resigned from the relevant positions of its subsidiaries, and will no longer hold any position
in the company after his resignation.
It is reported that Li Hui was the financial director, secretary of the board of directors, executive deputy general manager and general manager
of Henan Tailong Pharmaceutical Co.
, Ltd.
He is currently the chairman of Tailong Health Industry Investment Co.
, Ltd.
, and the director and vice chairman of
Henan Tailong Pharmaceutical Co.
, Ltd.
According to the data, Tailong Pharmaceutical is a pharmaceutical enterprise whose business covers four sectors: pharmaceutical preparations, traditional Chinese medicine pieces, drug research and development services and pharmaceutical material circulation, of which double huanglian oral liquid is an integral part of
the company's pharmaceutical preparation business.
Because double jaundice oral liquid has been included in the multi-provincial diagnosis and treatment plan, it is used for symptoms such as obvious sore throat, fever, muscle aches, fatigue, or cough
.
Tailong Pharmaceutical has also attracted the attention of the market and received short-term funds, and has walked out of 7 days and 5 boards
in November.
According to the company's disclosure, double jaundice oral liquid (concentrated type) and double jaundice oral liquid (children's type) are the company's core products
.
However, the double jaundice oral liquid does not seem to have obvious growth for the
company's performance.
Flush iFinD data shows that Tailong Pharmaceutical's net profit attributable to the parent has continued to decline since 2020, and the net profit attributable to the parent in 2021 increased year-on-year, but the trend is not lasting
.
According to the 2021 annual report, Tailong Pharmaceutical's sales of traditional Chinese medicine oral liquid were 429 million yuan, and the segment included multiple varieties
such as double jaundice oral, double gold combination, danshen oral liquid, and pediatric clear heat and cough oral liquid.
In the first half of 2022, the overall revenue of Tailong Pharmaceutical's pharmaceutical preparation sector was 185 million yuan, a year-on-year decrease of 23.
41%, accounting for only 21.
41%
of the total revenue.
In addition, affected by the decline in gross profit margin and the increase in sales expense ratio and R&D expense ratio, the third quarterly report of 2022 shows that Tailong Pharmaceutical achieved operating income of 1.
297 billion yuan from January to September 2022, and the net profit loss attributable to shareholders of the parent company was 56.
8783 million yuan, down 300.
99%
year-on-year.
For the reasons for the loss in the first three quarters of this year, the company said that in terms of main business, due to the impact of the ban and restriction policy on the sale of four types of drugs in many places in China, the company's sales of heat clearing and detoxification products were restricted, resulting in a decline in revenue and a decrease
in gross profit 。 It is worth mentioning that Tailong Pharmaceutical belongs to the concept of state-owned enterprise reform, the company has completed the change of control at the beginning of this year, the controlling shareholder belongs to the state-owned asset platform of Zhengzhou High-tech Zone, the company will continue to adhere to the "two-wheel drive" development strategy, focus on promoting the accelerated development of pharmaceutical R&D CXO service system, and maintain the steady growth of traditional Chinese medicine business; The new controlling shareholder has provided financial support of 576 million yuan to the company, and intends to invest 180 million yuan to set up a fund with the company to help the company's industrial development
.
In the next step, the company will take advantage of the capital advantages of the controlling shareholder and the resource advantages of its subordinate state-owned professional investment institutions to accelerate the industrial layout in the fields of biomedicine, CXO and general health, form synergy with the company's existing business, further promote the implementation of the company's two-wheel drive development strategy, and enhance the company's core competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.